We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+5.02%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$500M
AUM Growth
-$115M
Cap. Flow
-$85.2M
Cap. Flow %
-17.03%
Top 10 Hldgs %
48.26%
Holding
330
New
47
Increased
56
Reduced
65
Closed
116

Top Buys

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$14.3M
2
IKT icon
Inhibikase Therapeutics
IKT
+$12.7M
3
BIL icon
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
+$10.1M
4
ABVX
Abivax
ABVX
+$9.13M
5
RVMD icon
Revolution Medicines
RVMD
+$6.34M

Top Sells

Rank Stock Value
1
RPRX icon
Royalty Pharma
RPRX
+$27.8M
2
CYTK icon
Cytokinetics
CYTK
+$25.8M
3
KROS icon
Keros Therapeutics
KROS
+$21.9M
4
BBIO icon
BridgeBio Pharma
BBIO
+$19.9M
5
ASND icon
Ascendis Pharma A/S
ASND
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.69%
2 Financials 3.07%
3 Communication Services 1.32%
4 Technology 0.33%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ROIV icon
1
Roivant Sciences
ROIV
$23.6B
$41.5M 8.3%
3,508,694
+483,244
+16% +$5.71M
PTGX icon
2
Protagonist Therapeutics
PTGX
$8.54B
$39.4M 7.87%
1,020,333
+39,038
+4% +$1.7M
BOXX icon
3
Alpha Architect 1-3 Month Box ETF
BOXX
$13.1B
$35.9M 7.17%
325,450
+2,068
+0.6% +$227K
ZLAB icon
4
Zai Lab
ZLAB
$2.07B
$27.4M 5.47%
1,045,837
+513,383
+96% +$14.3M
IMVT icon
5
Immunovant
IMVT
$7.93B
$19.5M 3.9%
787,478
-344,229
-30% -$9.76M
CYTK icon
6
Cytokinetics
CYTK
$10.6B
$19.5M 3.89%
414,209
-496,973
-55% -$25.8M
BBIO icon
7
BridgeBio Pharma
BBIO
$16.4B
$18.6M 3.72%
678,857
-769,613
-53% -$19.9M
IKT icon
8
Inhibikase Therapeutics
IKT
$349M
$16.6M 3.31%
+5,103,005
New +$12.7M
BIL icon
9
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$47.1B
$12M 2.41%
131,786
+110,000
+505% +$10.1M
ABVX
10
Abivax
ABVX
$10.4B
$11.1M 2.21%
1,513,393
+991,781
+190% +$9.13M
MLYS icon
11
Mineralys Therapeutics
MLYS
$2.32B
$10.4M 2.07%
841,541
+112,140
+15% +$1.47M
ASND icon
12
Ascendis Pharma A/S
ASND
$16.5B
$9.83M 1.96%
71,402
-90,000
-56% -$11.8M
PCSC
13
DELISTED
Perceptive Capital Solutions
PCSC
$7.63M 1.53%
750,000
– –
RVMD icon
14
Revolution Medicines
RVMD
$38.4B
$7.44M 1.49%
170,000
+125,649
+283% +$6.34M
RZLT icon
15
Rezolute
RZLT
$453M
$6.66M 1.33%
1,359,208
-212,497
-14% -$1.07M
EDR
16
DELISTED
Endeavor Group Holdings, Inc.
EDR
$6.59M 1.32%
210,729
+87,922
+72% +$2.62M
CGON icon
17
CG Oncology
CGON
$6.1B
$6.19M 1.24%
215,750
+72,646
+51% +$2.49M
AVR
18
Anteris Technologies
AVR
$769M
$5.88M 1.17%
+1,052,968
New +$5.89M
AAM
19
DELISTED
AA Mission Acquisition Corp
AAM
$5.66M 1.13%
560,199
-450,000
-45% -$4.52M
XNCR icon
20
Xencor
XNCR
$1.45B
$5.39M 1.08%
234,607
-107,655
-31% -$2.47M
ZURA icon
21
Zura Bio
ZURA
$504M
$5.19M 1.04%
2,077,251
-1,693,398
-45% -$6.03M
PTGX icon
22
CALL
Protagonist Therapeutics
PTGX
$8.54B
$5.1M 1.02%
+132,000
New +$5.75M
ABUS icon
23
Arbutus Biopharma
ABUS
$845M
$5.08M 1.02%
1,554,802
-534,519
-26% -$1.97M
OACCU
24
Oaktree Acquisition Corp III Life Sciences Unit
OACCU
$5.07M 1.01%
+500,000
New +$5.04M
SRPT icon
25
Sarepta Therapeutics
SRPT
$1.64B
$4.86M 0.97%
40,002
+32,902
+463% +$4.03M
1
2 3 4 5

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $1.69B AUM
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

ADAR1 Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, ADAR1 Capital Management held 330 positions worth $500M, down 19% from $615M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

ADAR1 Capital Management withdrew a net $85.2M in Q4 2024, closing 116 positions and reducing 65 holdings. Its most notable exit was Syndax Pharmaceuticals, an estimated $6.74M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 86% a quarter earlier, followed by Financials and Communication Services.

Against the trend, ADAR1 Capital Management opened a new position in Inhibikase Therapeutics worth $16.6M.

  • ADAR1 Capital Management's largest Q4 2024 buy was Inhibikase Therapeutics: 5,103,005 shares worth $16.6M.
  • ADAR1 Capital Management added most to Zai Lab in Q4 2024, an estimated $14.3M increase.
  • ADAR1 Capital Management's biggest Q4 2024 reduction was Royalty Pharma, cutting an estimated $27.8M.
  • ADAR1 Capital Management fully exited Syndax Pharmaceuticals in Q4 2024, selling an estimated $6.74M.
  • ADAR1 Capital Management's ten largest holdings make up 48% of its $500M portfolio in Q4 2024.
  • ADAR1 Capital Management opened 47 new positions and closed 116 in Q4 2024.
  • ADAR1 Capital Management's portfolio value fell 19% quarter-over-quarter to $500M.

Based on ADAR1 Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.